KALA BIO, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer’s Purchases of Equity Securities Our Common Stock has been publicly traded on The Nasdaq Stock Market under the symbol “KALA” since July 20, 2017 in connection with our IPO. From July 20, 2017 through January 10, 2023 our Common Stock traded on The Nasdaq Global Select Market. Since January 11, 2023, our Common Stock has been trading on The Nasdaq Capital Market. Holders As of March 31, 2026, there were approximately 40 holders of record of our Common Stock. This number does not include beneficial owners whose shares are held by nominees in street name. Dividend Policy We have not declared or paid any cash dividends on our Common Stock since our inception. We intend to retain all available funds and any future earnings to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our Board may deem relevant. Information About our Equity Compensation Plans The information required by this item will be set forth in our Proxy Statement for our 2026 Annual Meeting of Stockholders (the “2026 Proxy Statement”) under the caption “Equity Compensation Plans”, and is incorporated herein by reference. Recent Sales of Unregistered Securities No unregistered securities were issued during the fiscal year ended December 31, 2025 that were not previously reported in a Quarterly Report on Form 10-Q or Current Report on Form 8-K Repurchase of Equity Securities We did not repurchase any of our equity securities during the fourth quarter of the fiscal year ended December 31, 2025. ​ Item 6. [Reserved] 86 Table of Contents